Company Description
Dominari Holdings Inc., through its subsidiaries, is engaged in wealth management, investment banking, sales and trading, and asset management.
It operates through two segments: Dominari Financial and Legacy AIkido. It offers full-service brokerage services, including exchange-traded and over-the-counter corporate equity and debt securities, money market instruments, exchange-traded options, municipal bonds, mutual funds, exchange-traded funds, and unit investment trusts; financial and wealth planning services, such as asset management, individual and corporate retirement solutions, insurance and annuity products, IRAs and 401(k) plans, U.S. stock plan services, education savings programs, and trust and fiduciary services; and margin lending services.
The company also provides financial advisory services to buyers and sellers on sales, divestitures, mergers, acquisitions, tender offers, privatizations, spin-offs, joint ventures, restructurings, and liability management; capital raising solutions through initial public offerings, follow-on offerings, confidentially marketed public offerings, registered directs, private investments in public equity, private placements, at-the-market offerings, and equity-linked offerings for corporate clients; institutional equity sales and trading; equity derivatives and index options; and trading in public and private debt securities, including investment and non-investment grade, distressed and convertible corporate securities.
In addition, it offers asset management solutions, such as separately managed accounts, discretionary advisory accounts, non-discretionary advisory accounts, alternative investments, and private market platform.
The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022.
Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
| Country | United States |
| Founded | 1967 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Anthony C. Hayes Esq. |
Contact Details
Address: 725 Fifth Avenue, 22nd Floor New York, New York 10022 United States | |
| Phone | (212) 393-4540 |
| Website | aikidopharma.com |
Stock Details
| Ticker Symbol | DOMH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000012239 |
| CUSIP Number | 008875304 |
| ISIN Number | US0088753043 |
| Employer ID | 52-0849320 |
| SIC Code | 6211 |
Key Executives
| Name | Position |
|---|---|
| Anthony C. Hayes Esq. | Chief Executive Officer and Chairman |
| Kyle Michael Wool | President and Director |
| George Michael Way CPA | Chief Financial Officer |
| Christopher Devall | Chief Operating Officer |
| Matthew B. McCullough | General Counsel |
| Jaime Mercado Jr. | Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2024 | 8-K | Current Report |
| Jun 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 21, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Dec 28, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
| Dec 28, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 18, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 8-K | Current Report |